OOIR: Observatory of International Research

Papers

(The H4-Index of Clinical Microbiology and Infection is 83. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis	970
COVID-19, SARS and MERS: are they closely related?	752
Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study	564
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review	526
Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis	488
Follow-up of adults with noncritical COVID-19 two months after symptom onset	484
Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting	463
Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study	448
Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China	423
Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay	412
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society	314
Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19	279
Novel SARS-CoV-2 variants: the pandemics within the pandemic	265
SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis	258
COVID-19 pandemic—a focused review for clinicians	258
COVID-19: don't neglect antimicrobial stewardship principles!	244
BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel	243
Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis	242
European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults	232
Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study	231
A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India	222
Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain	217
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors	214
Female gender is associated with long COVID syndrome: a prospective cohort study	206
Machine learning for clinical decision support in infectious diseases: a narrative review of current applications	205

Impact of COVID-19 on maternal and neonatal outcomes: a systematic review and meta-analysis	201
Diagnostic performance of seven rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients	198
Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres	197
Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis	188
Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients	187
Viable SARS-CoV-2 in various specimens from COVID-19 patients	174
Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study	166
Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study	165
Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital	155
Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans	154
Large-scale implementation of pooled RNA extraction and RT-PCR for SARS-CoV-2 detection	145
Diagnostic test accuracy of the BioFire® FilmArray® meningitis/encephalitis panel: a systematic review and meta-analysis	142
Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study	142
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis	138
Recommendations for antibacterial therapy in adults with COVID-19 – an evidence based guideline	137
Accuracy of a nucleocapsid protein antigen rapid test in the diagnosis of SARS-CoV-2 infection	131
Validation of a commercially available SARS-CoV-2 serological immunoassay	130
Pathogenesis and management of fracture-related infection	129
Diagnostic strategies for SARS-CoV-2 infection and interpretation of microbiological results	125
Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity	123
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1	119
Post–COVID-19 chronic symptoms: a postinfectious entity?	117
Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients—a multinational observational study by the European Confederation of Medical Mycology	116
Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs	114
Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review	114
Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit	114
Outbreak of Candida auris infection in a COVID-19 hospital in Mexico	114
Anosmia in COVID-19 patients	112
2020 list of human papillomavirus assays suitable for primary cervical cancer screening	111
How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST)	108
Evaluation of a rapid antigen test (Panbio™ COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients	102
Understanding the role of bacterial and fungal infection in COVID-19	100
Ibuprofen use and clinical outcomes in COVID-19 patients	100
Machine learning for microbial identification and antimicrobial susceptibility testing on MALDI-TOF mass spectra: a systematic review	99
A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients	98
ESCMID COVID-19 living guidelines: drug treatment and clinical management	98
Detection and infectivity potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) environmental contamination in isolation units and quarantine facilities	98
Oral amoxicillin and amoxicillin–clavulanic acid: properties, indications and usage	97
Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study	95
The role of asymptomatic and pre-symptomatic infection in SARS-CoV-2 transmission—a living systematic review	92
Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan	91
Cefepime neurotoxicity: thresholds and risk factors. A retrospective cohort study	91
Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019—a multi-centre observational study	91
Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohort	90
Stigma at the time of the COVID-19 pandemic	90
Association of COVID-19 with pregnancy outcomes in health-care workers and general women	90
Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status	90
Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARS-CoV-2 infection	90
Clinical course and factors associated with outcomes among 1904 patients hospitalized with COVID-19 in Germany: an observational study	88
Clinical characteristics of ambulatory and hospitalized patients with monkeypox virus infection: an observational cohort study	87

How to interpret and use COVID-19 serology and immunology tests	87
The interface between COVID-19 and bacterial healthcare-associated infections	87
Global prevalence of latent toxoplasmosis in pregnant women: a systematic review and meta-analysis	86
Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort	85
Clostridium difficile and One Health	85
Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary—the HUN-VE study	84
Molecular characterization of SARS-CoV-2 from the first case of COVID-19 in Italy	84
Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients	83
Current landscape in the discovery of novel antibacterial agents	83